Investigational antiviral pritelivir demonstrates efficacy and improved tolerability over current treatments for refractory HSV in high-risk patients.
A major UK clinical trial has shown that adding the corticosteroid dexamethasone to standard antiviral treatment for encephalitis (brain inflammation) caused by herpes simplex virus (HSV) does not ...
Italian pharma Alfasigma has penned a 125 million euro ($145 million) deal for the rights to an injectable form of an investigational herpes simplex virus (HSV) encephalitis treatment. Germany’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results